Cardiopulmonary bypass management and neurologic outcomes

An evidence-based appraisal of current practices

Charles W. Hogue, Christopher A. Palin, Joseph E. Arrowsmith

Research output: Contribution to journalArticle

Abstract

Neurologic complications after cardiac surgery are of growing importance for an aging surgical population. In this review, we provide a critical appraisal of the impact of current cardiopulmonary bypass (CPB) management strategies on neurologic complications. Other than the use of 20-40 μm arterial line filters and membrane oxygenators, newer modifications of the basic CPB apparatus or the use of specialized equipment or procedures (including hypothermia and "tight" glucose control) have unproven benefit on neurologic outcomes. Epiaortic ultrasound can be considered for ascending aorta manipulations to avoid atheroma, although available clinical trials assessing this maneuver are limited. Current approaches for managing flow, arterial blood pressure, and pH during CPB are supported by data from clinical investigations, but these studies included few elderly or high-risk patients and predated many other contemporary practices. Although there are promising data on the benefits of some drugs blocking excitatory amino acid signaling pathways and inflammation, there are currently no drugs that can be recommended for neuroprotection during CPB. Together, the reviewed data highlight the deficiencies of the current knowledge base that physicians are dependent on to guide patient care during CPB. Multicenter clinical trials assessing measures to reduce the frequency of neurologic complications are needed to develop evidence-based strategies to avoid increasing patient morbidity and mortality.

Original languageEnglish (US)
Pages (from-to)21-37
Number of pages17
JournalAnesthesia and Analgesia
Volume103
Issue number1
DOIs
StatePublished - Jul 2006

Fingerprint

Cardiopulmonary Bypass
Nervous System
Clinical Trials
Membrane Oxygenators
Vascular Access Devices
Excitatory Amino Acids
Knowledge Bases
Atherosclerotic Plaques
Hypothermia
Pharmaceutical Preparations
Thoracic Surgery
Multicenter Studies
Aorta
Patient Care
Arterial Pressure
Inflammation
Morbidity
Physicians
Glucose
Equipment and Supplies

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Cardiopulmonary bypass management and neurologic outcomes : An evidence-based appraisal of current practices. / Hogue, Charles W.; Palin, Christopher A.; Arrowsmith, Joseph E.

In: Anesthesia and Analgesia, Vol. 103, No. 1, 07.2006, p. 21-37.

Research output: Contribution to journalArticle

Hogue, Charles W. ; Palin, Christopher A. ; Arrowsmith, Joseph E. / Cardiopulmonary bypass management and neurologic outcomes : An evidence-based appraisal of current practices. In: Anesthesia and Analgesia. 2006 ; Vol. 103, No. 1. pp. 21-37.
@article{98d3f35928c54f58bf0b0f40192dccf8,
title = "Cardiopulmonary bypass management and neurologic outcomes: An evidence-based appraisal of current practices",
abstract = "Neurologic complications after cardiac surgery are of growing importance for an aging surgical population. In this review, we provide a critical appraisal of the impact of current cardiopulmonary bypass (CPB) management strategies on neurologic complications. Other than the use of 20-40 μm arterial line filters and membrane oxygenators, newer modifications of the basic CPB apparatus or the use of specialized equipment or procedures (including hypothermia and {"}tight{"} glucose control) have unproven benefit on neurologic outcomes. Epiaortic ultrasound can be considered for ascending aorta manipulations to avoid atheroma, although available clinical trials assessing this maneuver are limited. Current approaches for managing flow, arterial blood pressure, and pH during CPB are supported by data from clinical investigations, but these studies included few elderly or high-risk patients and predated many other contemporary practices. Although there are promising data on the benefits of some drugs blocking excitatory amino acid signaling pathways and inflammation, there are currently no drugs that can be recommended for neuroprotection during CPB. Together, the reviewed data highlight the deficiencies of the current knowledge base that physicians are dependent on to guide patient care during CPB. Multicenter clinical trials assessing measures to reduce the frequency of neurologic complications are needed to develop evidence-based strategies to avoid increasing patient morbidity and mortality.",
author = "Hogue, {Charles W.} and Palin, {Christopher A.} and Arrowsmith, {Joseph E.}",
year = "2006",
month = "7",
doi = "10.1213/01.ANE.0000220035.82989.79",
language = "English (US)",
volume = "103",
pages = "21--37",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Cardiopulmonary bypass management and neurologic outcomes

T2 - An evidence-based appraisal of current practices

AU - Hogue, Charles W.

AU - Palin, Christopher A.

AU - Arrowsmith, Joseph E.

PY - 2006/7

Y1 - 2006/7

N2 - Neurologic complications after cardiac surgery are of growing importance for an aging surgical population. In this review, we provide a critical appraisal of the impact of current cardiopulmonary bypass (CPB) management strategies on neurologic complications. Other than the use of 20-40 μm arterial line filters and membrane oxygenators, newer modifications of the basic CPB apparatus or the use of specialized equipment or procedures (including hypothermia and "tight" glucose control) have unproven benefit on neurologic outcomes. Epiaortic ultrasound can be considered for ascending aorta manipulations to avoid atheroma, although available clinical trials assessing this maneuver are limited. Current approaches for managing flow, arterial blood pressure, and pH during CPB are supported by data from clinical investigations, but these studies included few elderly or high-risk patients and predated many other contemporary practices. Although there are promising data on the benefits of some drugs blocking excitatory amino acid signaling pathways and inflammation, there are currently no drugs that can be recommended for neuroprotection during CPB. Together, the reviewed data highlight the deficiencies of the current knowledge base that physicians are dependent on to guide patient care during CPB. Multicenter clinical trials assessing measures to reduce the frequency of neurologic complications are needed to develop evidence-based strategies to avoid increasing patient morbidity and mortality.

AB - Neurologic complications after cardiac surgery are of growing importance for an aging surgical population. In this review, we provide a critical appraisal of the impact of current cardiopulmonary bypass (CPB) management strategies on neurologic complications. Other than the use of 20-40 μm arterial line filters and membrane oxygenators, newer modifications of the basic CPB apparatus or the use of specialized equipment or procedures (including hypothermia and "tight" glucose control) have unproven benefit on neurologic outcomes. Epiaortic ultrasound can be considered for ascending aorta manipulations to avoid atheroma, although available clinical trials assessing this maneuver are limited. Current approaches for managing flow, arterial blood pressure, and pH during CPB are supported by data from clinical investigations, but these studies included few elderly or high-risk patients and predated many other contemporary practices. Although there are promising data on the benefits of some drugs blocking excitatory amino acid signaling pathways and inflammation, there are currently no drugs that can be recommended for neuroprotection during CPB. Together, the reviewed data highlight the deficiencies of the current knowledge base that physicians are dependent on to guide patient care during CPB. Multicenter clinical trials assessing measures to reduce the frequency of neurologic complications are needed to develop evidence-based strategies to avoid increasing patient morbidity and mortality.

UR - http://www.scopus.com/inward/record.url?scp=33745846469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745846469&partnerID=8YFLogxK

U2 - 10.1213/01.ANE.0000220035.82989.79

DO - 10.1213/01.ANE.0000220035.82989.79

M3 - Article

VL - 103

SP - 21

EP - 37

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 1

ER -